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Reply to Stams et al Leukemia (2005) In their original letter 1 commenting to our paper, 2 Stams et al showed they failed to confirm statistical difference in asparagine synthetase (AS) expression levels in TEL/AML1 pos paediatric ALL patients with or without subsequent relapses. This difference might be considered clinically relevant since data on patients from different protocols are compared.
Variant dosage of specific chemotherapeutics and their combinations used in the different protocols may lead to dissimilar treatment results (as it was clearly shown with E2A/ PBX1 aberration). 3 Therefore, this discrepancy might be exposing a potentially very significant biological feature of TEL/ AML1 pos patients, hitherto unknown. However, data on treatment protocols are unavailable in the study of Stams et al. Such data are needed to substantiate their doubts about the prognostic significance of AS in TEL/AML1 pos ALL. Another explanation of a contrast of these studies is the difference in reference genes. In their justification of GAPDH use as a reference gene, Stams et al neglect that the deletions were reported to include regions centromeric as well as telomeric from the TEL gene. 4, 5 Even if the coding sequence of the GAPDH gene would be intact, the deletion could affect regulating sequences often localised at a larger distance. The reported differences of AS are subtle, and normalised expression is sensitive to minor changes in reference gene expression. Showing the raw AS expression data or any other non-normalised RQ-PCR data might only blur the real picture. It would help the discussion and justify the use of GAPDH if the expression of various reference genes in a set of samples with t(12;21) are compared. Then, we can proceed to look whether AS has a different prognostic significance in different chemotherapeutic protocols.
